人胰高血糖素样肽类似物抗糖尿病新药阿必鲁泰  

Albiglutide:a new anti-diabetic drug of human glucagon-like peptide analogue

作　　者：陈兰婷 朱颐申[1] 范学海[1] 李文惠[1] 韦萍[1] 

机构地区：[1]南京工业大学生物与制药工程学院,南京211816

出　　处：《中国新药杂志》2014年第17期1969-1972,共4页Chinese Journal of New Drugs

基　　金：江苏高校优势学科建设工程资助

摘　　要：阿必鲁泰皮下注射剂是一种长效胰高血糖素样肽-1(GLP-1)受体激动剂,每周皮下注射1次,主要结合饮食与运动用于改善2型糖尿病患者的血糖控制,欧洲药物管理局和美国食品药品监督管理局分别于2014年3月26日和4月15日批准其上市。相比安慰剂,阿必鲁泰在控制血糖,减少糖基化血红蛋白、空腹血糖、餐后血糖波动以及减肥等方面都有显著作用,且长期稳定性和安全性较好,已成为治疗2型糖尿病的一种新选择。本文对其药理作用、临床研究及安全性等做一综述。Albiglutide, a long-acting human glucagon-like peptide analogue, was approved by the European Medicines Agency at 26th March and by the U. S. Food and Drug Administration at 15th April, 2014. A subcutaneous injection of albiglutide, once a week, can improve glycemic control along with diet and exercise in adultswith type 2 diabetes. The clinical studies of albiglutide for the treatment of type 2 diabetes have been summarized. Its safety and effectiveness have been also evaluated. Compared with placebo, albiglutide improves glycemic controlwith significant reductions from baseline in glycosylated hemoglobin, in fasting plasma glucose and postprandial glu- cose excursions, and in weight loss. Due to its better long-term stability and safety, albiglutide is a new choice forthe treatment of type 2 diabetes.

关 键 词：阿必鲁泰 胰高血糖素样肽类似物 2型糖尿病 Β细胞 临床研究 

分 类 号：R972.6[医药卫生—药品]